Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.
Top Stages
1 past transactions
Oscine Therapeutics
Acquisition in 2020
Oscine Therapeutics is a biotechnology company founded on research from the University of Rochester Medical Center. The company focuses on developing a cell therapy platform that leverages stem cell science to address central nervous system (CNS) diseases. Oscine Therapeutics generates bipotential astrocyte-oligodendrocyte glial progenitor cells, which are designed to replace lost, damaged, or dysfunctional glial cells in patients suffering from degenerative diseases and conditions affecting white matter. By advancing this innovative approach, Oscine Therapeutics aims to expand therapeutic options and enhance the potential for curing CNS diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.